RECORD1

Xarelto® 10 mg once daily in the RECORD1 study demonstrated superior VTE prevention to enoxaparin 40 mg once daily, with no significant increase in risk of bleeding in patients undergoing THR surgery.2

RECORD2

In the RECORD2 study, extended-duration thromboprophylaxis with Xarelto 10 mg once daily was superior to short-duration thromboprophylaxis with enoxaparin 40 mg once daily in reducing VTE, with no significant increase in the risk of bleeding in patients undergoing THR surgery.3

RECORD3

Xarelto 10 mg once daily in the RECORD3 study demonstrated superior VTE prevention to enoxaparin 40 mg once daily, with no significant increase in the risk of bleeding in patients undergoing TKR surgery.4

RECORD4

Xarelto 10 mg once daily in the RECORD4 study demonstrated superior efficacy in VTE prevention compared with enoxaparin 30 mg twice daily, with no increase in risk of bleeding in patients undergoing TKR surgery.69

Xarelto in Practice Q&A

With the introduction of any new therapeutic option, there are often questions regarding its use in clinical practice. These answers to some commonly asked questions are designed to provide further guidance to the physician about the appropriate use of Xarelto.

  • 5 - Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82(9):777-782.
  • 6 - Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
  • 7 - Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.
  • 105 - Turpie AGG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011;105:444–453.
  • 2 - Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
  • 3 - Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39.
  • 4 - Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
  • 69 - Turpie AGG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-1680
  • 11 - Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205.
Thrombosis
Formation of a clot inside a blood vessel.
Venous thromboembolism
A disease process beginning with a blood clot occurring within the venous system, including deep vein thrombosis and pulmonary embolism.
Thromboprophylaxis
Preventative treatment for blood clotting.
Efficacy
The ability of a drug to produce the desired effect.